

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TenNor Therapeutics (Suzhou) Limited

丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

POLL RESULTS OF THE ANNUAL SHAREHOLDERS' MEETING HELD ON MONDAY, JUNE 29, 2026

The board of directors (the “**Board**”) of TenNor Therapeutics (Suzhou) Limited (the “**Company**”) hereby announces that the 2025 annual shareholders’ meeting of the Company (the “**ASM**”) was held at Unit 701, Block B7, BioBay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area of China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu, PRC at 2:00 p.m. on Monday, June 29, 2026. Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), any vote of Shareholders at a general meeting must be taken by poll. The ASM was chaired by Dr. Ma Zhenkun, Chairman of the Board.

POLL RESULTS OF THE ASM

At the ASM, the proposed resolutions set out in the notice of the ASM of the Company dated June 8, 2026 were put to vote by poll and duly passed. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated June 8, 2026 (the “**Circular**”).

As at the date of the ASM, the total number of issued Shares of the Company was 52,328,926 H Shares, being the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the ASM. The Company did not hold any treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System). The Shareholders and proxies attending the ASM represented an aggregate of 17,102,586 Shares carrying voting rights in the Company, representing approximately 32.68% of the total number of Shares carrying voting rights in the Company as at the date of the ASM. No Shareholder was entitled to attend the ASM but was required under Rule 13.40 of the Listing Rules to abstain from voting in favour of any resolution at the ASM. No Shareholder was required under the Listing Rules to abstain from voting on any resolution at the ASM. No Shareholder has stated its intention in the Circular that it would vote against any proposed resolutions or that it would abstain from voting at the ASM. The executive Director, Dr. Ma Zhenkun, the non-executive Director, Dr. Song Gaoguang, and the independent non-executive Directors, Dr. Li Leping and Dr. Ni Lin, attended the ASM in person. The independent non-executive Director, Mr. Lee Wai Kong, Albert, did not attend the ASM due to official duties.

The poll results in respect of the resolutions proposed at the ASM were as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the resolution on the 2025 work report of the board of directors of the Company	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the resolution on the 2025 performance report of the independent non-executive directors of the Company	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To consider and approve the resolution on the 2025 annual financial report of the Company	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the resolution on the 2025 profit distribution plan of the Company	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
5.	To consider and approve the resolution on the remuneration plan for the directors of the current session of the board of directors of the Company	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
6.	To consider and approve the resolution on the engagement of the Company's auditor for the year 2026	17,102,586 (100.00%)	0 (0.00%)	0 (0.00%)
As more than half of the votes were cast in favour of resolutions numbered 1 to 6 above, such resolutions were duly passed as ordinary resolutions.				

The Company's H Share registrar, Tricor Investor Services Limited, and two shareholder representatives of the Company acted as scrutineers for the poll at the ASM and were responsible for the counting and scrutiny of the votes.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
*Chairman of the Board, Executive Director,
 Chief Executive Officer and General Manager*

Hong Kong, June 29, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.